Investigation of the tumor microenvironment (TME) revealed that melanoma patients responding to the combination of ICPi against PD1 and CTLA-4 had an enhanced frequency of CD45RO+ EOMES+ T cells with an effector memory, but not terminally exhausted phenotype [68]. The gene discussed is CTLA4; the disease is neoplasm.